Fig. 2.
PFS according to ERCC1 expression. Patients with moderate or high levels of ERCC1 had shorter progression-free survival [median PFS: 5.1 months, mean PFS ± SE: 6.6 months ±1.3 (95% CI: 4.1–9)] than patients with low or no ERCC1 production [median PFS: 10.2 months, mean PFS ± SE: 15.7 months ±4.8 (95% CI: 6.3–25.2)] (p = 0.027). PFS, Progression Free Survival